Vancouver, BC (FSCwire) - M Pharmaceutical, Inc. (CSE:MQ, OTCQB: MPHMF, FWB:T3F2 ), (the "Company" or “M Pharma”), is pleased to announce Brian Keane as the Interim President and CEO for the Company, subject to regulatory approval.
Brian has over 17 years of capital markets, Investing and C-level consulting experience. Brian has invested in or has advised/restructured over 75 emerging growth companies in the US, Canada, Caribbean and Asia, representing over $2 billion in transaction value. He has advised several buy-side investment funds as well as has worked at several investment banks that include: Rodman & Renshaw, LLC,, Ladenburg Thalmann & Co, and TechVest where he focused on natural resource/life science and biotech companies. He earned a Bachelor of Science degree from the University of Scranton and a Juris Doctor from New York Law School. Brian will remain the managing member of Qualified Capital, his C-Level and Family Office consultancy company during this interim role.
“Brian has the requisite knowledge and capital markets experience to execute M Pharma’s technology development plan, raise the necessary capital and explore an acquisition strategy while providing leadership to the management team pending the appointment of a full time CEO”, said the Board of Directors.
“I welcome this opportunity to assist the Company in its transition and look forward to focusing the development of its current portfolio of technologies while exploring growth opportunities to address the unmet treatment needs for the growing obesity market.” said Brian.
About M Pharmaceutical Inc.
Formed in early 2015, M Pharmaceutical Inc. is a clinical-stage company developing innovative technologies for obesity and weight management. Of the Company’s portfolio of technologies, its primary focus will be on its developing its Trimeo capsules, which are temporary controllable pseudobezoars for non-invasive gastric volume reduction for the treatment of obesity.
M Pharmaceutical trades on the Canadian Securities Exchange (CSE) under the ticker symbol “MQ” as well as on the OTCQB as “MPHMF” and FWB (Frankfurt Stock Exchange) as “T3F2.”
For more information contact:
Notice regarding Forward Looking Statements: This news release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the commercialization of the rights to the eMosquito, Trimeo and Trimtec biomedical technologies. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company's disclosure documents which can be found under the Company's profile on www.sedar.com and the Company’s filings to the CSE at www.cnsx.ca. Such risk factors may cause the inability of the Company to successfully commercialize any of its biomedical technologies.